Synthesis and Evaluation of a Series of $^{99m}$Tc(CO)$_3^+$ Lisinopril Complexes for In Vivo Imaging of Angiotensin-Converting Enzyme Expression

Frank J. Femia$^1$, Kevin P. Maresca$^1$, Shawn M. Hillier$^1$, Craig N. Zimmerman$^1$, John L. Joyal$^1$, John A. Barrett$^1$, Omer Aras$^2$, Vasken Dilsizian$^2$, William C. Eckelman$^1$, and John W. Babich$^1$

$^1$Molecular Insight Pharmaceuticals Inc., Cambridge, Massachusetts; and $^2$Department of Nuclear Medicine, University of Maryland, Baltimore, Maryland

In animal models of cardiac disease and in human congestive heart failure, expression of angiotensin-converting enzyme (ACE) is upregulated in the failing heart and has been associated with disease progression leading to cardiac failure and fibrosis. To develop probes for imaging ACE expression, a series of di(2-pyridylmethyl)amine (D) chelates capable of binding M(CO)$_3^+$ (M = technetium, rhenium) was conjugated to lisinopril by acylation of the ε-amine of the lysine residue with a series of di(2-pyridylmethylamino)alkanoic acids where the distance of the chelator from the lisinopril core was investigated by varying the number of methylene spacer groups to produce di(2-pyridylmethyl)amine(C$_x$)lisinopril analogs: D(C$_4$)lisinopril, D(C$_5$)lisinopril, and D(C$_6$)lisinopril. The inhibitory activity of each rhenium complex was evaluated in vitro against purified rabbit lung ACE and was shown to vary directly with the length of the methylene spacer: Re[D(C$_6$)lisinopril], IC$_{50}$ = 1,146 nM; and Re[D(C$_5$)lisinopril], IC$_{50}$ = 114 nM, as compared with lisinopril, IC$_{50}$ = 4 nM. The in vivo specificity for ACE was determined by examining the biodistribution of the $^{99m}$Tc-[D(C$_6$)lisinopril] analog in rats with and without pretreatment with unlabeled lisinopril. Uptake in the lungs, a tissue that constitutively expresses ACE, was 15.2 percentage injected dose per gram at 10 min after injection and was dramatically reduced by pretreatment with lisinopril, supporting ACE-mediated binding in vivo. Planar anterior imaging analysis of $^{99m}$Tc-[D(C$_6$)lisinopril] corroborated these data. Thus, high-affinity $^{99m}$Tc-labeled ACE inhibitor has been designed with potency similar to that of lisinopril and has been demonstrated to specifically localize to tissues that express ACE in vivo. This agent may be useful in monitoring ACE as a function of disease progression in relevant diseases such as heart failure.

Key Words: lisinopril; $^{99m}$Tc; angiotensin-converting enzyme (ACE); congestive heart failure; SPECT

DOI: 10.2967/jnumed.107.049064

Congestive heart failure is a pathologic condition characterized by a progressive decrease in left ventricular (LV) function and is associated with high morbidity and mortality (1). Recent reclassification of heart failure into 4 stages by the American College of Cardiology and American Heart Association (ACC-AHA) emphasizes the development of management strategies that will prevent evolution of heart failure from those who are susceptible to heart failure (stage A) or have asymptomatic LV dysfunction (stage B) to those who are symptomatic of (stage C) and develop end-stage (stage D) heart failure (2). Thus, imaging approaches that can monitor progression of heart failure from stages A–D or the reversal of the LV remodeling process will favorably affect the growing social and financial burden on the health care system.

Accumulating evidence from clinical and experimental studies indicates that the renin-angiotensin system and its primary effector peptide, angiotensin II, are linked to the pathophysiology of LV remodeling and heart failure (3). In animal and human models, increased expression of angiotensin-converting enzyme (ACE) has been associated with cardiac fibrosis (4,5). In patients with heart failure, inhibition of ACE with ACE inhibitors has proven to have a favorable effect on LV remodeling and patient outcome (6,7). However, because of genetic differences, significant variations in individual responses to ACE inhibitors have been observed. Moreover, questions regarding the timing of ACE inhibitor initiation, optimal dosage, and proper monitoring remain unanswered. Thus, the development of a new radiotracer that targets the renin-angiotensin system represents an important first step toward image-guided individualized therapy. If successful, the latter will go a long way for realizing the goals of the ACC-AHA preventive strategy in heart failure.

On the basis of preliminary autoradiography results in hearts from patients with congestive heart failure in which ACE expression correlated with the extent of disease (5), it appears that the development of radiopharmaceuticals that
enable the detection of myocardial ACE expression may offer the potential of monitoring LV remodeling at the molecular level. Noninvasively identifying patients with increased ACE expression, prospectively, before the transition to replacement fibrosis and remodeling occurs, coupled with the appropriate intervention, may lead to preserved LV function, thereby improving overall prognosis.

This study builds on our previous efforts to design a high-affinity ACE inhibitor that incorporates 99mTc (8). We used 99mTc because of its excellent imaging characteristics and widespread availability (9), as well as the suitability of the previously described technetium-tricarbonyl (Tc(CO)3) core (10) to form robust complexes with our recently described single amino acid chelate technology based on the di(pyridylmethyl)amine chelator (11). We chose lisinopril as the starting structural ACE inhibitor motif because of its higher affinity for tissue ACE (12–14) and the chemical flexibility it offers to incorporate di(pyridylmethyl)amine moiety. This article describes the first, to our knowledge, high-affinity, low molecular weight, 99mTc-labeled compound that shows specific binding to ACE in vivo.

MATERIALS AND METHODS

General

Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich Chemical Co. and used without further purification. Lisinopril was obtained from LKT Laboratories. All ligands of the type D(Cx)lisinopril (where x is the total number of carbons in the tether including the methylene and carbonyl carbons) and their intermediates were previously reported and synthesized according to published literature procedures (11,15,16). The starting material, [Re(CO)3(H2O)3]Br, was synthesized according to previously described methods (17). Elemental analysis was performed by Desert Analytics, electrospray mass spectrometry by HT Laboratories, and 1H nuclear magnetic resonance (NMR) spectroscopy by Custom NMR Services. The 99mTc was obtained from a 99Mo-99mTc radio-nuclide generator (Cardinal Health). Radiolabeling kits were used (Isolink; Tyco Healthcare).

Synthesis

The desired lisinopril analogs were synthesized as shown in Figure 1. Commercially available ε-amino acids were converted to the corresponding di(2-pyridylmethylamino)alkanoic acids (11,15,16) via reductive amination under standard conditions in good yields (16). Activation of the free acid under standard peptide-coupling conditions followed by addition of lisinopril afforded the desired free ligand conjugates (8,17,18) in moderate yields. The free ligands were directly radiolabeled with 99mTc or complexed with rhenium as described later.

General Synthesis of Cx Ligand

Pyridine-2-carboxaldehyde (2 Eq) was added to a mixture of the desired aminoalkanoic acid (1 Eq) and sodium triacetoxycarbonylhydride (2.5 Eq) in dichloroethane (15 mL) at room temperature. The suspension was stirred at room temperature for 8 h. The mixture was quenched with water and diluted with chloroform (100 mL). The organic layer was separated and washed with water (3 × 100 mL) and saturated sodium chloride solution (100 mL) and dried over sodium sulfate. After removal of the solvent under reduced pressure, the residue was purified via flash column chromatography MeOH-CHCl3 (1:9) as the eluent to provide the desired di(2-pyridylmethylamino)alkanoic acids as viscous light yellow syrups.

Characterization of Di(2-Pyridylmethylamino)Alkanoic Acids

4-(Bis(pyridin-2-ylmethylamino)butanoic acid (1): Yield = 84% (4.6 g). 1H NMR (CDCl3, ppm): 8.54 (d, 2H), 7.71 (t, 2H), 7.46 (d, 2H), 7.22 (t, 2H), 3.86 (s, 4H), 2.67 (t, 2H), 2.35 (t, 2H), 1.68 (m, 2H), CO2H (not seen). 13C NMR (CDCl3, ppm): 176.9, 158.8, 148.5, 137.4, 123.7, 122.6, 59.7, 54.1, 33.1, 22.6. MS(ESI): m/z 286 (M + H)+, m/z 284 (M – H)-.

5-(Bis(pyridin-2-ylmethylamino)pentanoic acid (2): Yield = 42% (2.10 g). 1H NMR (CDCl3, ppm): 8.51 (d, 2H), 7.64 (t, 2H), 7.51 (d, 2H), 7.13 (t, 2H), 3.78 (s, 4H), 2.54 (t, 2H), 2.26 (t, 2H), 1.59 (m, 4H), CO2H (not seen). 13C NMR (CDCl3, ppm): 177.1, 159.2, 148.3, 137.2, 123.4, 122.4, 59.7, 54.1, 34.4, 26.5, 22.8. MS(ESI): m/z 300 (M + H)+, m/z 298 (M – H)-.

8-(Bis(pyridin-2-ylmethylamino)octanoic acid (3): Yield = 63% (2.81 g). 1H NMR (CDCl3, ppm): 8.52 (d, 2H), 7.63 (t, 2H), 7.52 (d, 2H), 7.16 (t, 2H), 3.86 (s, 4H), 2.54 (t, 2H), 2.35 (t, 2H), 1.68–1.51 (m, 4H), 1.33–1.25 (m, 6H), CO2H (not seen). 13C NMR (CDCl3, ppm): 177.2, 159.3, 148.3, 137.1, 123.3, 122.3, 59.7, 54.5, 34.6, 29.2, 29.1, 27.1, 26.8, 25.0. MS(ESI): m/z 342 (M + H)+, m/z 340 (M – H)-.

High-Performance Liquid Chromatography (HPLC) Analysis

Analysis of the radiolabeled and nonradiolabeled compounds was performed on an HPLC instrument (ProStar; Varian Inc.) equipped with a pumping system (210 Solvent Delivery Module; Varian Inc.), a detector (345 UV-Vis Detector; Varian Inc.) (A, 254 nm), and a sodium iodide scintillation counter (Bicron Frisk-Tech; Saint-Gobain Industrial Ceramics Inc.). HPLC analysis of the radiolabeled lisinopril derivatives was performed using C-18 reversed-phase HPLC (250 × 4.6 mm, 5 μm; Vydac) eluted with 0.1% trifluoroacetic acid in water (solvent A) to 0.1% trifluoroacetic acid in acetonitrile (solvent B).

General Synthesis of D(Cx) Lisinopril

The desired di(2-pyridylmethylamino)alkanoic acid (1 Eq) was dissolved in acetonitrile (10 mL). 1.5 Eq of 1-hydroxybenzoazole, 1.5 Eq of N-(3-dimethylaminopropyl)-N'-ethyldiimidide
hydroxyl, and 2 Eq of triethylamine were dissolved in acetonitrile (10 mL) and added to the reaction solution. The mixture was stirred at room temperature under argon and formation of the active ester monitored by thin-layer chromatography. On complete formation of the desired intermediate, the reaction was concentrated to an oil, which was redissolved in methylene chloride (10 mL) and quenched with water (10 mL). The organic layer was separated and washed with water (1 × 20 mL) and a saturated sodium chloride solution (1 × 20 mL). The organic layer was dried over sodium sulfate and filtered, and the solvent was removed to yield a white solid. The white solid was dissolved in acetonitrile (10 mL), and lisinopril (1.1 Eq) was added in 10 mL of water. A 20% solution of triethylamine/acetomitrile (10 mL) was added and the reaction mixture stirred for 15 min. The sample was concentrated to afford the crude product. The resulting residue was purified by C-18 reversed-phase HPLC to yield the desired product as a white solid.

Characterization of D(C)xLisinopril

(S)-1-((S)-6-(5-(bis(pyridin-2-ylmethyl)amino)pentanamido)-2-((S)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid (6): Yield = 35% (0.57 g). 1H NMR (CDCl3, ppm): 8.50 (m, 2H), 7.65 (m 2H), 7.50 (m, 2H), 7.13 (m, 8H), 3.92 (d, 4H), 3.69–2.62 (m, 11H), 2.27–1.46 (m, 18H), 2 CO2H (not seen), NH (not seen). MS(ESI): m/z 688 (M + H)⁺, m/z 686 (M – H)⁻. Analysis calculated for C₃₈H₅₀N₆O₆·H₂O: C, 64.75; H, 7.44; N, 11.92; O, 15.89. Found: C, 64.77; H, 7.35; N, 11.92; O, 16.07.

(S)-1-((S)-6-(5-(bis(pyridin-2-ylmethyl)amino)octanamido)-2-((S)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid (6): Yield = 35% (0.57 g). 1H NMR (CDCl3, ppm): 8.50 (d, 2H), 7.63 (m, 2H), 7.50 (m, 2H), 7.13 (m, 8H), 3.85 (d, 4H), 3.69–2.53 (m, 11H), 2.23–1.22 (m, 24H), 2 CO2H (not seen), NH (not seen). MS(ESI): m/z 730 (M + H)⁺, m/z 728 (M – H)⁻. Analysis calculated for C₃₇H₄₈N₆O₆: C, 65.93; H, 7.83; N, 11.25; O, 14.99. Found: C, 65.64; H, 8.21; N, 11.20; O, 14.48.

General Procedure for Radiolabeling of ⁹⁹ᵐTc-(CO)₃(D(C)x)Lisinopril

¹⁹⁹mTc-(CO)₃(H₂O)₃⁺ was prepared following the methods by James et al. (18), using radiolabeling kits (Isolink). Sodium pertechnetate (7,400 MBq [200 mCi]) in saline (2.5 mL) was added to a radiolabeling kit (Isolink), and the vial was placed in an oil bath at 100°C. The reaction was heated for 45 min, and 1N HCl (200 μL) was then added to neutralize the reaction mixture. The product, ¹⁹⁹mTc-(CO)₃(H₂O)₃⁺, was removed from the vial via syringe and added to another vial containing D(C)xLisinopril (100 μL of a 1 mg/mL solution in methanol) followed by an additional amount of methanol (0.5 mL). The reaction was heated for 1 h at 80°C and the sample loaded onto a purifying column (C18 Sep-Pak; Waters). Purification of the final radiolabeled product was accomplished by use of a cartridge (Sep-Pak Plus C18 Cartridge; Waters), which was activated with ethanol (5 mL) and then washed with water (3 × 60 mL). The reaction mixture was loaded onto the cartridge in water (20 mL), and unreacted ⁹⁹mTc, which may include Tc(CO)₃⁺ and TcO₄⁻, was washed off the column with additional water (3 × 20 mL). The radiolabeled product was eluted off the cartridge with ethanol (3 mL). The solvent was removed under a stream of nitrogen and the ⁹⁹mTc-labeled derivative reconstituted in 10% ethanol/saline. The radiochemical purity of the final ⁹⁹mTc complexes was greater than or equal to 98% and radiochemical yield was generally greater than or equal to 88% as determined by HPLC analysis.

General Procedure for Preparation of Re(CO)₃D(C)xLisinopril

[Re(CO)₃(H₂O)₃]Br (1 Eq) was added to a round-bottom flask containing D(C)xLisinopril (1 Eq) dissolved in methanol. The reaction was heated to 80°C and stirred for 4 h. After heating, the solvent was removed and the sample was purified by HPLC. The corresponding rhenium derivatives were HPLC-purified using a gradient elution starting with 95% buffer A (0.1% trifluoroacetic acid in water) to 5% buffer B (0.1% trifluoroacetic acid in acetonitrile) solution and ending with 5% buffer A to 95% buffer B solution on a C-18 reversed-phase column (Dynamax; Varian Inc.) (250 × 21.4 mm, 5 μm) at a flow rate of 15 mL/min over 60 min. The structures of the final pure samples were determined by ¹H NMR and mass spectroscopy.

Characterization of Re(CO)₃D(C)xLisinopril

Tricarbonylrhenium(I)-(S)-1-((S)-6-(5-(bis(pyridin-2-ylmethyl)amino)pentanamido)-2-((S)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid (7): Yield = 23% (0.2 g). 1H NMR (dimethyl sulfoxide [DMSO]-d₆, ppm): 8.75 (d, 2H), 7.92 (m, 3H), 7.63 (m, 2H), 7.34–7.10 (m, 5H), 5.05 (m, 4H), 4.30–2.93 (m, 11H), 2.57–1.22 (m, 16H), 2 CO2H (not seen). MS(ESI): m/z 944 (M + H)⁺, m/z 942 (M – H)⁻.

Tricarbonylrhenium(I)-(S)-1-((S)-6-(5-(bis(pyridin-2-ylmethyl)amino)pentanamido)-2-((S)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid (8): Yield = 34% (0.30 g). 1H NMR (DMSO-d₆, ppm): 8.77 (m, 2H), 7.97 (m, 2H), 7.89 (t, 1H), 7.56 (d, 2H), 7.44 (m, 2H), 7.24–7.12 (m, 5H), 4.91 (s, 4H), 4.20–2.81 (m, 12H), 2.66–1.32 (m, 18H), 2 CO2H (not seen). MS(ESI): m/z 958 (M + H)⁺, m/z 956 (M – H)⁻.

Tricarbonylrhenium(I)-(S)-1-((S)-6-(5-(bis(pyridin-2-ylmethyl)amino)octanamido)-2-((S)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid (9): Yield = 29% (0.17 g). 1H NMR (DMSO-d₆, ppm): 8.77 (d, 2H), 7.97 (m, 2H), 7.84 (m, 1H), 7.66 (m, 2H), 7.37 (m, 2H), 7.22–7.12 (m, 5H), 4.91 (s, 4H), 4.21–2.80 (m, 12H), 2.67–1.22 (m, 24H), 2 CO2H (not seen). MS(ESI): m/z 1,000 (M + H)⁺, m/z 998 (M – H)⁻.

In Vitro ACE Activity Assay

The ability of lisinopril and the lisinopril derivatives to inhibit ACE activity was determined using an ACE diagnostic kit (ACE Color; Fujirebio, Inc.) according to the manufacturer’s instructions. Purified rabbit lung ACE (3.3 μU; Sigma Chemicals) was incubated for 20 min with the test compounds at concentrations of 10 μM to 0.1 nM in 0.125 mL of a solution of substrate (p-hydroxybenzoyl-glycine-l-histidyl-l-leucine) at 37°C, resulting in the hydrolysis to p-hydroxybenzoyl-glycine and l-histidyl-l-leucine. Developer solution (0.375 mL) containing dipiracure was added to cleave p-hydroxybenzoyl-glycine and form p-hydroxybenzoic acid. Quinoneimine dye was produced by oxidation and condensation of the p-hydroxybenzoic acid with 4-aminopyrpyrine and sodium
metaperiodate. The color change was monitored at 505 nm in a spectrophotometer (Genesys 8 UV-VIS; Spectronic Unicam).

Rat Tissue Distribution
Tissue distribution studies of 99mTc-(CO)3D(C8)lisinopril administered via the tail vein as a 1.85-MBq/kg (50 μCi/kg) bolus injection (approximately 0.37 MBq [10 μCi]/rat) in a constant volume of 0.1 mL were performed in separate groups of male Sprague–Dawley rats (n = 5/time point). To demonstrate specificity in vivo, some rats were injected intravenously with non-radiolabeled lisinopril, 0.6 mg/kg (approximately 272 nmol/rat), 5 min before injection of 99mTc-(CO)3D(C8)lisinopril. The animals were euthanized by asphyxiation with carbon dioxide at 10 min, 30 min, 1 h, or 2 h after injection. Blood, heart, lungs, liver, spleen, kidneys, large and small intestines (with contents), testes, skeletal muscle, and adipose were excised, weighed, wet, transferred to plastic tubes, and counted in an automated γ-counter (LKB Model 1282; Wallac Oy). Aliquots of the injected dose were also measured to convert the counts per minute in each tissue sample to percentage injected dose per organ. Tissue radioactivity levels of 99mTc-(CO)3D(C8)lisinopril expressed as percentage injected dose per gram (%ID/g) were determined by converting the decay-corrected counts per minute to the percentage dose and dividing by the weight of the tissue or organ sample.

Planar Anterior Imaging
Sprague–Dawley rats were anesthetized with sodium pentobarbital (50 mg/kg administered intraperitoneally) and randomly assigned to groups of 99mTc-(CO)3D(C8)lisinopril alone or 99mTc-(CO)3D(C8)lisinopril pretreated with lisinopril (n = 3/group). To demonstrate specificity in vivo, lisinopril (0.6 mg/kg; approximately 272 nmol/rat) was administered to 3 animals at 5 min before injection of 99mTc-(CO)3D(C8)lisinopril. 99mTc-(CO)3D(C8)lisinopril, 185 MBq/kg (5 mCi/kg; approximately 37 MBq/rat [1 mCi/rat]), was then administered intravenously to all 6 animals. Baseline planar anterior imaging consisted of five 1-min consecutive images acquired using a dual-head γ-camera with a low-energy, all-purpose collimator (DSX-LI; SMV America) at 5, 10, 15, 20, 30, and 60 min after injection. Regions of interest (ROIs) were drawn over the lung, liver, intestines, and background (soft tissue) for each animal at each imaging time point. ROIs were quantified and expressed in counts and normalized to the background at that same time point.

RESULTS
A series of di(2-pyridylmethyl)amine chelates capable of binding M(CO)3+ core were conjugated to lisinopril by acylation of the ε-amine of the lysine residue with a series of di(2-pyridylmethylamino)alkanoic acids. The distance of the chelator from the lisinopril core was explored by varying the number of methylene units (n) from 3 to 7 in the alkyl chain to afford D(C3)lisinopril, D(C5)lisinopril, and D(C8)lisinopril, as shown in Figure 1.

The rhenium tricarbonyl Re(CO)3+ complexes of D(C3)lisinopril were prepared and tested for their ability to inhibit ACE activity in vitro. As illustrated in Table 1, the inhibitory activity of each of the Re(CO)3+-complexes, as evaluated in vitro against purified rabbit lung ACE, varied directly with the number of methylene spacer units (Re(CO)3D(C8)lisinopril, IC50 = 3 nM; Re(CO)3D(C3)lisinopril, IC50 = 144 nM; and Re(CO)3D(C5)lisinopril, IC50 = 1,146 nM). The analog with the 7-carbon methylene spacer tether, Re(CO)3D(C8)lisinopril, exhibited activity that was similar to that of the parent molecule, lisinopril (IC50 = 4 nM). A similar relationship was observed with the free ligands, D(C3)lisinopril.

D(C8)lisinopril was radiolabeled with 99mTc and injected into rats to examine tissue uptake and retention. The excess ligand was not separated from the technetium chelate, resulting in a specific activity at the end of synthesis of 38,000 MBq/μmol (1,027 mCi/μmol). Therefore, an injection of 0.37 MBq (10 μCi)/rat represents approximately 0.01 nmol/rat and the injection for the imaging studies represents 1 nmol/rat. Table 2 shows the rat tissue distribution of 99mTc-(CO)3D(C8)lisinopril. The radiotracer was detected at varying levels in all tissues examined and readily decreased over time. Uptake was greatest in the lungs, a tissue with high ACE expression, reaching 15.2 %ID/g at 10 min after injection, with 3.93 %ID/g remaining at 2 h. Clearance appeared to be primarily via the hepatobiliary route as demonstrated by increasing radioactivity in the intestines over time. Specific uptake of 99mTc-(CO)3D(C8)lisinopril was demonstrated by coinjection with 272 nmol/rat of nonradiolabeled lisinopril, resulting in significantly reduced lung uptake, 0.17 %ID/g at 10 min after injection. The lisinopril-sensitive decrease in uptake of 99mTc-(CO)3D(C8)lisinopril in other tissues is likely due to the detection of low levels of ACE reported to be expressed in these tissues (19) or in the endothelial cells of the blood vessels associated with the tissues (20).

Whole-body imaging of control and lisinopril-treated rats was performed to examine the ability of 99mTc-(CO)3D(C8)lisinopril to noninvasively monitor ACE expression in vivo. Figure 2 shows representative in vivo anterior whole-body planar images acquired at 10 min after 99mTc-(CO)3D(C8)lisinopril injection. The images show high lung, liver, intestine, and bladder radiotracer uptake. Lung uptake was completely inhibited by pretreatment with nonradiolabeled lisinopril. ROIs were drawn over the lungs, intestines, and soft tissue (background) to determine the intensity of the signal in target organs at each time point. As shown in Table 3, quantification of the planar images cor-

### Table 1

<table>
<thead>
<tr>
<th>x</th>
<th>Re(CO)3 IC50 (nM)</th>
<th>+ Re(CO)3 IC50 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>83</td>
<td>1,146</td>
</tr>
<tr>
<td>5</td>
<td>43</td>
<td>144</td>
</tr>
<tr>
<td>8</td>
<td>19</td>
<td>3</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>4</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA = not applicable.
Anterior view of whole-body planar images shows in vivo distribution of $^{99m}$Tc-(CO)$_3$D(C$_8$)lisinopril and $^{99m}$Tc-(CO)$_3$D(C$_8$)lisinopril + lisinopril-treated rats at 10 min after injection. Animals are arranged head to head.

FIGURE 2.
the left ventricle of rats after myocardial infarction induced by coronary artery ligation. The increase in ACE was predominantly in the border zone and scar tissue (24,25). In addition, ACE mRNA increases in the left ventricle of senescent rats, which is suggested to be triggered by age-related mechanical changes to the heart (27). ACE activity is also increased in the heart from cardiomyopathic hamsters when compared with age-matched controls (28).

In patients with heart failure, inhibition of the renin-angiotensin system with ACE inhibitors has proven to favorably affect LV remodeling and patient outcome. In humans, preliminary data using cardiac-tissue sections from patients with congestive heart disease have demonstrated an upregulation of ACE (5) and increased expression of ACE mRNA in patients with late-stage heart failure (29). The availability of an imaging technique that quantitates ACE levels in vivo will allow further investigation of these observations, as the heart will be in its natural milieu.

Radio-labeled ACE inhibitors, in the form of $^3$H-captopril, were first described in the early 1980s and were used for in vitro autoradiography to examine the distribution of ACE in rat brain (30). Later, Mendelsohn’s group prepared $^{125}$I-MK351A to examine ACE tissue distribution, focusing on the brain and heart (31). MK351A (N-[(s)-l-carboxy-3-phenylpropyl]-lysyl-tyrosyl-L-proline) was synthesized by reacting the tyrosine moiety with the ε-amino of the lysine residue in lisinopril to form a molecule that can be readily iodinated. MK351A has a high affinity for ACE ($K_d = 2 \text{nM}$), similar to that of lisinopril ($K_d = 0.13 \text{nM}$) and has an affinity higher than that of captopril ($K_d = 22 \text{nM}$) (Fig. 3). This increased affinity resulted in higher resolution in autoradiography experiments when compared with $^3$H-captopril (32). These data validate the approach of adding significant bulk to the ε-amino of lysine in lisinopril without compromising affinity for ACE. Two $^{18}$F-labeled ACE inhibitors have been described, $^{18}$F-fluorocaptopril and $^{18}$F-fluorobenzoyl-lisinopril (21,33). $^{18}$F-fluorocaptopril was developed by Hwang et al. and evaluated as a PET tracer (33). However, although fluorocaptopril (FCAP) showed target-specific binding to tissues that express ACE, it has several shortcomings and therefore was not our first choice as a radiopharmaceutical development candidate. The sulphydryl group in FCAP can form captopril disulfide dimers and mixed disulfides of captopril with endogenous sulphydryl compounds, including cysteine, glutathione, and proteins. This makes determination of the amount of free FCAP available to bind to the enzyme difficult because of the possible equilibrium involved. In addition, it may be difficult to chromatographically purify the compound without artifacts. Also, Schuster’s group has reported that both the cis and the trans isomer of FCAP exist in plasma, inferring that isomeric conversion is a phenomenon that occurs in vivo (34). Finally, captopril is thought to have a higher affinity for plasma ACE than the tissue ACE, whereas other ACE inhibitors, such as lisinopril,
have a higher affinity for tissue ACE than vascular ACE (12–
14,35). Because our goal is to study ACE in heart tissue, the
compounds with higher tissue affinity would be more suit-
able starting motifs for the design of novel radioligands.
Analogs of lisinopril, with larger substituents on the ε-amino
of lysine, have been reported (15). These compounds incor-
porate rhodium or palladium through bulky iminophosphor-
anophosphine moieties yet maintain high affinity for ACE.
Thus, the literature suggested that radiolabeled analogs can
be prepared with substantial mass added to the lysine of
lisinopril while still maintaining high affinity for ACE.

Several biochemical probes radiolabeled with halogens
retain the desired biochemical properties and exhibit reten-
tion in target organs (21,31,33). We chose to investigate
analogs that incorporate ⁹⁹ᵐTc to be used with SPECT as
this strategy offers the advantage of widespread availability
of ⁹⁹ᵐTc and SPECT cameras. To date, the best example of
a successful low–molecular weight, ⁹⁹ᵐTc-labeled targeted
radiotracers is TRODAT1 (36), which images dopamine
transporters and has shown promise for the diagnosis of a
variety of neurologic disorders (37).

Although a link between ACE expression and cardiac
disease clearly exists, an association of ACE expression has
also been demonstrated for other diseases. ACE protein and
mRNA levels are increased on leukemic cells in patients
with acute myeloid leukemia (38). In addition, ACE protein
associated with infiltrating inflammatory cells is increased
in atherosclerotic plaques (39). Finally, increased ACE mRNA
has been detected in kidneys of patients with diabetes (40).
Therefore, several potential uses for a molecular imaging
pharmaceutical that recognizes ACE exist.

CONCLUSION

Information on the course of disease progression through
noninvasive molecular imaging offers the possibility of
improving patient management. Heart failure is a disease
that has many etiologies but far fewer means of predicting
progression or response to therapy. A means of noninvasively
monitoring biologic phenomena that indicate the severity of
heart failure or the likelihood of progression could poten-
tially be used to improve therapeutic management and
thereby slow or reverse progression in the patient with heart
failure.

By exploiting the tridentate chelate concept based on the
single-amino-acid chelate approach, we prepared a series of
lisinopril derivatives capable of forming robust complexes
with technetium and rhenium. The distance between the
metal chelate and the lisinopril ligand was varied using
methylenic spacer groups to maximize binding to the ACE
enzymatic binding site. The most potent compound, ⁹⁹ᵐTc-
(CO)₃(DC₅H₅)lisinopril, displayed ACE inhibitory activity
similar in potency to the starting lisinopril molecule. The
tissue-distribution studies showed high uptake in organs
containing high ACE expression such as the lungs, and
pretreatment with lisinopril demonstrated that the uptake
was specific. This is the first description, to our knowledge, of
a high-affinity ACE inhibitor that contains ⁹⁹ᵐTc.

ACKNOWLEDGMENTS

We thank Tomika Coleman for her assistance with the
studies conducted at the University of Maryland. This work
was supported in part by grant IR43HL075918-01 from the
National Institutes of Health, National Heart, Lung, and
Blood Institutes.

REFERENCES

and management of chronic heart failure in the adult: executive summary a
report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (committee to revise the 1995 guidelines for the
evaluation and management of heart failure): developed in collaboration with the
International Society for Heart and Lung Transplantation; Endorsed by the Heart
3. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical
implications—a consensus paper from an international forum on cardiac
2000;35:569–582.
knockout mice display less left ventricular remodeling and improved survival
5. Dilsizian V, Eckelman WC, Loredo ML, Jagoda EM, Shirani J. Evidence for
tissue angiotensin-converting-enzyme in explanted hearts of ischemic cardio-
6. Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enal-
april on survival in patients with reduced left ventricular ejection fractions and
325:293–302.
7. Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril
on mortality and the development of heart failure in asymptomatic patients with
derivatives of lisinopril for imaging angiotensin converting enzyme (ACE). In:
Mazzi U, Giron MC, eds. Technetium, Rhenium and Other Metals in Chemistry
9. Jurisso SS, Lydon JD. Potential technetium small molecule radiopharmaceuti-
organoametallacyclic copper complex of technetium for the labeling of biomolecules:
synthesis of [⁹⁹ᵐTc(OH)₂(CO)₃(C₅H₅)]⁺ from [⁹⁹ᵐTcO₄]⁻ in aqueous solution and its
11. Wei L, Babich JW, Eckelman WC, Zubieta JA. Rhenium tricarbonyl core
2209.
12. Shirani J, Loredo ML, Eckelman WC, Jagoda EM. Dislizian V. Imaging the
2:78–86.
13. Cashman DW, Wang FL, Fung WC, Harvey CM, DeForest JM. Differentiation
of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition
306.
activation of cardiac angiotensin converting enzyme in experimental heart
15. Pandurangi RS, Katti KV, Stillwell L, Barnes CL. Retention of inhibitory
potency of an ACE inhibitor conjugated with Rh(III) and Pd(II) (iminophos-
16. Levadala MK, Banerjee SR, Maresca KP, Babich JW, Zubieta JA. Direct
reductive alkylation of amino acids: synthesis of bifunctional chelates for nuclear
Synthesis and Evaluation of a Series of $^{99m}$Tc(CO)$_3^{+}$ Lisinopril Complexes for In Vivo Imaging of Angiotensin-Converting Enzyme Expression

Frank J. Femia, Kevin P. Maresca, Shawn M. Hillier, Craig N. Zimmerman, John L. Joyal, John A. Barrett, Omer Aras, Vasken Dilsizian, William C. Eckelman and John W. Babich


This article and updated information are available at: [http://jnm.snmjournals.org/content/49/6/970](http://jnm.snmjournals.org/content/49/6/970)

Information about reproducing figures, tables, or other portions of this article can be found online at: [http://jnm.snmjournals.org/site/misc/permission.xhtml](http://jnm.snmjournals.org/site/misc/permission.xhtml)

Information about subscriptions to JNM can be found at: [http://jnm.snmjournals.org/site/subscriptions/online.xhtml](http://jnm.snmjournals.org/site/subscriptions/online.xhtml)